Excess Cases Of Pancreatic Cancer, Colon Cancer, Rectal Cancer, And Lung Cancer Observed In Belviq Safety Clinical Trial
On February 13, 2020 the FDA requested Eisai Inc. to voluntarily withdraw its diet drug Belviq because a Belviq safety clinical trial shows an increased occurrence of cancer cases. The Belviq FDA Drug Safety Communication announcing this Belviq recall, "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market", noted that excess cases of pancreatic cancer, colon cancer, rectal cancer, and lung cancer were observed.
For some background about the Belviq safety clinical trial showing the diet drug Belviq is associated with an increased occurrence of cancer cases see our January 14, 2020 article, "Belviq Cancer Risk Warning Alert Issued To Patients And Doctors In January 2020 FDA Drug Safety Communication".
The Data Summary section of this Belviq FDA Drug Safety Communication set forth these findings from the Belviq safety clinical trial:
There was a numerical imbalance in the number of patients with malignancies, with one additional cancer observed per 470 patients treated for one year. During the course of the trial, 462 (7.7 percent) patients treated with [Belviq (lorcaserin)] were diagnosed with 520 primary cancers compared to the placebo group, in which 423 (7.1 percent) patients were diagnosed with 470 cancers. Imbalances in specific cancers including pancreatic, colorectal, and lung contributed to the observed overall imbalance in cancer cases. There was no apparent difference in the incidence of cancer over the initial months of treatment, but the imbalance increased with longer duration on [Belviq (lorcaserin)].
Strictly Confidential, No Obligation.
The FDA approved Belviq as a weight-loss drug in 2012.
The Belviq safety clinical trial leading to this February 2020 Belviq recall is the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients – Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) clinical trial.
We are investigating possible Belviq lawsuits involving for patients who have been diagnosed with cancer, including but not limited to:
- Pancreatic Cancer
- Colorectal Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
For people with possible Belviq lawsuits -- personal injury or wrongful death -- we encourage them to submit a Belviq Case Evaluation Form. It is free, confidential, and there is no obligation.
Of course, we will continue to monitor the medical research for more information about the specific types of cancer cases associated with Belviq.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)